Nektar Therapeutics: Leerink Partners initiates coverage with outperform rating; target price $130
NKTR•Leerink Partners initiated coverage of Nektar Therapeutics with an outperform rating and a $130 target price.
Related News
Unum Group: Wells Fargo raises target price to $102 from $100
UNM•
eBay: Wells Fargo cuts target price to $91 from $92
EBAY•
Garmin wins multiple marine industry awards at IBEX 2026 trade show
GRMN•
Neurocrine Biosciences target price cut to $150 from $164
NBIX•
Iridex says two-year study shows MicroPulse TLT lowers intraocular pressure in early-to-advanced glaucoma
IRIX•